Clinical trials & research studies
There are 50 clinical trials and research studies matching essential thrombocythemia near you. Last updated 2026-11-15.
Research outlook What's coming for Essential thrombocythemia: the next 6 months to 5 yearsData from ClinicalTrials.gov and NIH RePORTER. Last reviewed 2026-11-15 by the Find a Trial editorial team.
Describe your situation. We find matching studies and explain them in plain English.
How it works
Write it the way you'd tell a friend: the diagnosis, how far along it is, what treatments you've had. No medical codes needed.
AI reads each study's rules for who can join, ranks the ones that fit you, and rewrites them in plain English: what's being tested and who it's for.
Every match links to the study's official listing and its contact person. Take it to your doctor and ask the team about pre-screening.
What we search
Most trial finders only show clinical trials. We also include early research the NIH is funding, which can point to what's coming next. Use the Show buttons to pick one or both.
New drugs, devices, therapies and procedures. Many are enrolling patients now. Source: ClinicalTrials.gov.
Lab and population studies funded by the NIH. Most don't enroll patients, but some labs look for volunteers. Source: NIH RePORTER.
Not sure what to type?
Questions
Yes. There's no account, no sign-up and nothing to pay. We don't run any of the studies; we help you find them.
Not unless you ask. You can choose to get email updates about a study; otherwise we never ask for your name, email or phone number. You decide whether to contact a study team, using the details on each listing.
Your diagnosis plus anything that affects who can join: the stage or type, treatments you've had, other conditions, and your age. Leave out your name and contact details.
Open a match and contact the study team listed there. They'll ask a few screening questions to check if you qualify. Pre-screening is free and doesn't commit you to anything. It's a good idea to talk it over with your doctor too.
No. We help you find and understand studies. Your doctor and the study team decide whether a study is right for you.
PHASE3 · Incyte Corporation · NCT07623200
This phase 3 study tests whether INCA033989 can help people with essential thrombocythemia who have a CALR mutation and have already had cytoreductive therapy, compared to the best available treatment.
Why this is a good match: Phase 3 for CALR-mutant ET after cytoreductive therapy
Conditions: Essential Thrombocythemia, calreticulin, mutCALR
PHASE1; PHASE2 · Jubilant Therapeutics Inc. · NCT07612280
This study tests whether taking JBI-802 by mouth can be safe and helpful for adults with essential thrombocythemia or related blood cancers that involve high platelet counts.
Why this is a good match: Oral JBI-802 targets high platelet counts in ET
Conditions: Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasms, Myeloproliferative Neoplasms
PHASE2 · Step Pharma, SAS · NCT06786234
This study will try daily oral STP938 in adults with high‑risk essential thrombocythaemia who are resistant to or intolerant of hydroxycarbamide to see if it safely lowers platelet counts.
Why this is a good match: Daily STP938 for high-risk hydroxycarbamide resistant ET
Conditions: Essential Thrombocythaemia, Essential Thrombocythemia, High risk, Resistant to or Intolerant of Hydroxycarbamide Therapy, Resistant to or Intolerant of Hydroxyurea Therapy
PHASE2 · Xiamen Amoytop Biotech Co., Ltd. · NCT06552429
This study is testing if a new medication called Peginterferon α-2b can help people with essential thrombocythemia who haven't had success with or can't tolerate their current treatment.
Why this is a good match: Peginterferon α-2b for ET intolerant to prior therapy
Conditions: Essential Thrombocythemia, Peginterferon α-2b, hydroxyurea resistant, hydroxyurea intolerant
NA · Tongji Hospital · NCT06734637
This study is testing if a weekly injection of Peginterferon can help people with Essential Thrombocythemia and Polycythemia Vera feel better and stay safe while using the treatment.
Why this is a good match: Weekly peginterferon symptom and safety study in ET
Conditions: Essential Thrombocythemia, Polycythemia Vera, Essential thrombocythemia, Polycythemia vera, Peginterferon α-2b
PHASE1 · Damora Therapeutics · NCT07849231
This study tests DMR-001 alone for CALR-mutant essential thrombocythemia or myelofibrosis, and in combination with ruxolitinib for CALR-mutant myelofibrosis.
Why this is a good match: DMR-001 trial includes CALR-mutant essential thrombocythemia
Conditions: Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, CALR mutation
PHASE3 · Merck Sharp & Dohme LLC · NCT06351631
This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.
Why this is a good match: Bomedemstat safety and durability data in ET patients
Conditions: Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
University Hospital, Angers · NCT05440838
We will test whether genetic mutations and cytokine levels at diagnosis can predict who will respond to hydroxyurea or pegylated interferon in people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis.
Why this is a good match: Biomarkers predicting hydroxyurea or pegIFN response in ET
Conditions: Myeloproliferative Neoplasm
PHASE1 · Janssen Research & Development, LLC · NCT06150157
This study is testing a new treatment called JNJ-88549968 to see if it is safe and effective for people with CALR-mutated myeloproliferative neoplasms.
Why this is a good match: Targets CALR-mutated MPNs potentially including ET
Conditions: Neoplasms
PHASE1 · Incyte Corporation · NCT06034002
This study is testing a new treatment called INCA033989, alone and with another drug, to see if it’s safe and effective for people with myeloproliferative neoplasms who have certain mutations.
Why this is a good match: Tests INCA033989 safety and efficacy in MPNs including ET
Conditions: Myeloproliferative Neoplasms, Myelofibrosis, Essential thrombocythemia, CALR mutation
PHASE1 · Incyte Corporation · NCT07008118
This trial tests whether INCA035784 is safe and tolerable in adults with CALR‑mutated myeloproliferative neoplasms who have already received prior therapies.
Why this is a good match: Safety study in CALR‑mutated MPNs after prior therapies
Conditions: Myeloproliferative Neoplasms, Myelofibrosis, Essential thrombocythemia, CALR mutation
PHASE1 · Incyte Corporation · NCT07441694
This Phase 1 study will test whether INCA036978, given alone or with standard therapy, is safe and tolerable for adults with myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia.
Why this is a good match: Phase 1 testing INCA036978 alone and with standard therapy in MPNs
Conditions: Myeloproliferative Neoplasms, Myelofibrosis, Essential thrombocythemia, Polycythemia Vera
PHASE2 · Massachusetts General Hospital · NCT04644211
This study is testing if the drug Ruxolitinib can help reduce symptoms for people with low-risk essential thrombocythemia and polycythemia vera.
Why this is a good match: Ruxolitinib symptom reduction trial for low-risk ET
Conditions: Essential Thrombocythemia, Polycythemia Vera, Sympton Burden
PHASE3 · University Hospital, Brest · NCT05198960
This study is testing whether the blood thinners Apixaban and Rivaroxaban can prevent blood clots better than low-dose aspirin in patients with certain blood disorders who are at high risk.
Why this is a good match: Direct oral anticoagulants versus aspirin for thrombosis prevention
Conditions: Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients
NA · University Hospital, Bordeaux · NCT07119970
This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.
Why this is a good match: NETosis markers predict clotting risk in JAK2V617F ET
Conditions: Myeloproliferative Neoplasm, Myeloproliferative Disorders, Myeloproliferative neoplasms, Thrombosis, Neutrophil extracellular traps
Wake Forest University Health Sciences · NCT06480591
This study is trying to understand why people with CALR mutations in myeloproliferative neoplasms have a different risk of blood clots compared to those with JAK2 mutations by looking at certain blood markers.
Why this is a good match: Studies clot risk differences between CALR and JAK2 mutation carriers
Conditions: Myeloproliferative Neoplasm, Thrombosis, JAK2 mutation, CALR mutation
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT07203768
This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.
Why this is a good match: Identifies features linked to JAK2 ET progression to PV
Conditions: Polycythemia Vera, Thrombocythemia
NA · University Hospital, Angers · NCT04942080
This study is trying to see if tracking a specific genetic change in the blood can help doctors understand how myeloproliferative neoplasms progress in patients over time.
Why this is a good match: Tracks genetic changes to monitor MPN progression
Conditions: Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage, CALR
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11258551
Researchers will look at how the common JAK2V617F mutation together with loss of genes on chromosome 20q drive progression from polycythemia vera or essential thrombocythemia to myelofibrosis to find new treatment targets for people with these blood cancers.
Why this is a good match: Studies JAK2V617F plus 20q loss driving progression
['FUNDING_R01'] · TEMPLE UNIV OF THE COMMONWEALTH · NIH-10849882
This study is looking at blood cancers called myeloproliferative neoplasms (MPNs) to see how certain genetic changes can help doctors choose the best treatments and create new ones that target the cancer's root cause, with the hope of improving current therapies and helping patients stay in remission longer.
Why this is a good match: Genomic profiling to guide targeted therapy in MPNs
Conditions: Cancers, neoplasm/cancer
